Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Jun 15 2012 Posted in Press releases

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.

May 28 2021

Urgent actions are needed now to prevent a collapse of diagnostic testing.

Invitation: “Can EU citizens afford their medicines? The economic crisis and access to medicines in Europe“

Apr 29 2013 Posted in Advocacy news

For more information, please find the full invitation here

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Announcement: The award winners of the prestigious EHA-ASH Translational Research in Hematology Training Award are selected

Nov 25 2014 Posted in Press releases

The winners of the TRTH 2015 Awards are:

Name

Nationality

Name

Nationality

Ileana Antony-Debre

French

Jean-Baptiste Micol

French

Pavan Bachireddy

American

Christopher Ott

American

Lucile Couronné

French

Carsten Riether

German

Moniek de Witte

Dutch

Anindita Roy

British

Ammon Fager

American

Melody Smith

American

Gillian Horne

British

Zuzana Tothova

Slovakian

Moonjung Jung

South Korea

Marcin Wlodarski

Polish

Jonas Samuel Jutzi

Swiss - German

Yuh-Ying Yeh

Taiwanese

Milka Koupenova-Zamor

American - Bulgarian

Sasan Zandi

Iranian

Marwan Kwok

British

Patricia Maiso

Spain

Are you interested in joining the…

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

Jun 10 2013 Posted in Press releases

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Mar 27 2013 Posted in Press releases

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

Jul 26 2016 Posted in Advocacy news

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.